Thomas Berger
#170,689
Most Influential Person Now
Researcher
Thomas Berger's AcademicInfluence.com Rankings
Thomas Bergercomputer-science Degrees
Computer Science
#10435
World Rank
#10960
Historical Rank
Computational Linguistics
#2630
World Rank
#2656
Historical Rank
Machine Learning
#4771
World Rank
#4825
Historical Rank
Artificial Intelligence
#5138
World Rank
#5205
Historical Rank
Download Badge
Computer Science
Thomas Berger's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Thomas Berger Influential?
(Suggest an Edit or Addition)Thomas Berger's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. (2003) (627)
- Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo (2009) (515)
- Antibody to aquaporin-4 in the long-term course of neuromyelitis optica (2008) (399)
- Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders (2011) (390)
- Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. (1999) (359)
- The spectrum of MOG autoantibody-associated demyelinating diseases (2013) (323)
- T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system (1993) (286)
- Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein (2014) (244)
- Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging (2016) (242)
- Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome (2017) (232)
- Patterns of Trauma among the Neandertals (1995) (230)
- Experimental autoimmune encephalomyelitis: the antigen specificity of T lymphocytes determines the topography of lesions in the central and peripheral nervous system. (1997) (206)
- Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies (1999) (194)
- Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. (2011) (182)
- Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. (2012) (182)
- Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100 beta molecule, a calcium binding protein of astroglia (1994) (177)
- Apolipoprotein E ε4 is associated with rapid progression of multiple sclerosis (2001) (166)
- Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain (2006) (162)
- Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases (2017) (162)
- Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica (2013) (158)
- Patterns of Antibody Binding to Aquaporin-4 Isoforms in Neuromyelitis Optica (2010) (148)
- Smoking is a risk factor for early conversion to clinically definite multiple sclerosis (2008) (137)
- International multicenter examination of MOG antibody assays (2019) (125)
- Cerebrospinal Fluid B Cells Correlate with Early Brain Inflammation in Multiple Sclerosis (2008) (122)
- Distinction and Temporal Stability of Conformational Epitopes on Myelin Oligodendrocyte Glycoprotein Recognized by Patients with Different Inflammatory Central Nervous System Diseases (2013) (116)
- The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls (2001) (114)
- Lack of association between antimyelin antibodies and progression to multiple sclerosis. (2007) (111)
- Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis (2001) (110)
- Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort (2013) (96)
- Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis (2005) (92)
- Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination (2017) (91)
- A comparative study of the relative bioavailability of different interferon beta preparations (2000) (91)
- Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they? (2017) (89)
- Antibodies as biological markers for pathophysiological processes in MS (2006) (88)
- Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barré syndrome. (2003) (88)
- Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. (2020) (87)
- Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies (2016) (86)
- Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders (2003) (82)
- Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI. (2021) (81)
- Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis. (2001) (81)
- Olfactory threshold is impaired in early, active multiple sclerosis (2011) (78)
- Escalating immunotherapy of multiple sclerosis--new aspects and practical application. (2004) (73)
- Increased Expression of Apolipoprotein D Following Experimental Traumatic Brain Injury (1999) (69)
- Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event (2005) (66)
- Pro‐inflammatory activation of microglia in the brain of patients with sepsis (2018) (65)
- Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis (2019) (62)
- Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS (2007) (62)
- Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity (2004) (62)
- Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases). (2004) (61)
- Increased intrathecal production of apolipoprotein D in multiple sclerosis (2001) (61)
- Acute and non-resolving inflammation associate with oxidative injury after human spinal cord injury (2020) (60)
- Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF (2007) (60)
- Neuromyelitis Optica in Austria in 2011: To Bridge the Gap between Neuroepidemiological Research and Practice in a Study Population of 8.4 Million People (2013) (60)
- Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults (2008) (59)
- Myelin oligodendrocyte glycoprotein‐DNA vaccination induces antibody‐mediated autoaggression in experimental autoimmune encephalomyelitis (2000) (59)
- Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis (2004) (57)
- Fulminant demyelinating encephalomyelitis (2015) (56)
- Antimyelin antibodies with no progression to multiple sclerosis. (2007) (56)
- Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts (2016) (55)
- Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing-remitting disease course of multiple sclerosis (2005) (54)
- A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions. (2003) (51)
- Serum antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in Miller Fisher syndrome (1997) (50)
- Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors (2017) (50)
- ‘No evidence of disease activity’ – is it an appropriate surrogate in multiple sclerosis? (2018) (49)
- Mutations in the gene for toll-like receptor 4 and multiple sclerosis. (2003) (49)
- Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study (2016) (48)
- Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients (2006) (48)
- Multiple sclerosis: Disease biomarkers as indicated by pathophysiology (2007) (47)
- Encephalitogenic and neuritogenic T cell responses to the myelin-associated glycoprotein (MAG) in the Lewis rat (1999) (47)
- Worldwide Incidence and Prevalence of Neuromyelitis Optica (2020) (46)
- International consensus on quality standards for brain health-focused care in multiple sclerosis (2018) (44)
- Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper) (2021) (44)
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders? (2018) (44)
- Clinical, radiological, immunological and pathological findings in inflammatory CNS demyelination-possible markers for an antibody-mediated process (2001) (42)
- Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations (2007) (42)
- Induction of experimental autoimmune encephalomyelitis by CD4+ T cells specific for an astrocyte protein, S100 beta. (1997) (41)
- Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b. (2001) (40)
- Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders (2011) (40)
- Persistency of neutralizing antibodies depends on titer and interferon-beta preparation (2012) (39)
- Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria (2018) (37)
- Sarcopenia in Neurological Patients: Standard Values for Temporal Muscle Thickness and Muscle Strength Evaluation (2020) (36)
- Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycoprotein: Influence of relapses and immunomodulatory treatments (2006) (34)
- Natalizumab treatment reduces endothelial activity in MS patients (2010) (33)
- Acute aphasia in multiple sclerosis. (2001) (33)
- Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases (2013) (33)
- Neonatal Kyphectomy in the Patient With Myelomeningocele (2003) (32)
- Interferon-β1b augments activation-induced T-cell death in multiple sclerosis patients (1999) (31)
- Patient-reported quality of life in multiple sclerosis differs between cultures and countries: a cross-sectional Austrian–German–Polish study (2011) (29)
- Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study (2017) (29)
- The effect of rhythmic-cued motor imagery on walking, fatigue and quality of life in people with multiple sclerosis: A randomised controlled trial (2017) (29)
- Multiple sclerosis and COVID‐19: How many are at risk? (2020) (29)
- A critical comparison of frequently used methods for the analysis of tumor necrosis factor-alpha expression by human immune cells. (2000) (29)
- Costs and quality of life of multiple sclerosis in Austria (2006) (29)
- Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome (2020) (28)
- Macular ganglion cell–inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis (2020) (28)
- Antibody biomarkers in CNS demyelinating diseases – a long and winding road (2015) (28)
- Regional prevalence and clinical benefit of implantable cardioverter defibrillators in Brugada syndrome. (2010) (26)
- Monoclonal antibodies in the treatment of multiple sclerosis. (2009) (26)
- Biological markers for multiple sclerosis. (2007) (26)
- Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis (2020) (26)
- Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy (2003) (26)
- Current therapeutic recommendations in multiple sclerosis (2009) (26)
- Peripapillary retinal nerve fibre layer thinning rate as a biomarker discriminating stable and progressing relapsing–remitting multiple sclerosis (2019) (26)
- Change of olfactory function as a marker of inflammatory activity and disability progression in MS (2019) (25)
- Autonomic instability, as measured by pupillary unrest, is not associated with multiple sclerosis fatigue severity (2002) (25)
- Impaired body image in patients with multiple sclerosis (2011) (25)
- High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study (2009) (25)
- Daytime sleepiness is not increased in mild to moderate multiple sclerosis: a pupillographic study. (2005) (25)
- NMDA receptor antibodies (2015) (24)
- Epitope Specificity of Neutralizing Antibodies Against IFN-β (2004) (24)
- How Does Fingolimod (Gilenya®) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis? (2013) (24)
- Comparison of Diagnostic Accuracy of Microscopy and Flow Cytometry in Evaluating N-Methyl-D-Aspartate Receptor Antibodies in Serum Using a Live Cell-Based Assay (2015) (23)
- Real‐life clinical use of natalizumab and fingolimod in Austria (2018) (23)
- Replication study of multiple sclerosis (MS) susceptibility alleles and correlation of DNA-variants with disease features in a cohort of Austrian MS patients (2012) (23)
- Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis (2020) (22)
- Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases (2013) (22)
- Features of intrathecal immunoglobulins in patients with multiple sclerosis (2010) (22)
- COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry (2021) (22)
- Serum neurofilament light chain withstands delayed freezing and repeated thawing (2020) (22)
- The effect of nabilone on neuropsychological functions related to driving ability: an extended case series (2005) (22)
- Increased serum levels of soluble CD14 indicate stable multiple sclerosis (2006) (21)
- Interferon-β antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies (2006) (21)
- Antibodies to myelin oligodendrocyte glycoprotein in HIV-1 associated neurocognitive disorder: a cross-sectional cohort study (2010) (21)
- Antibody response to myelin oligodendrocyte glycoprotein and myelin basic protein depend on familial background and are partially associated with human leukocyte antigen alleles in multiplex families and sporadic multiple sclerosis (2002) (21)
- Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis. (2005) (21)
- Multiple sclerosis spasticity daily management: retrospective data from Europe (2013) (20)
- NMDA receptor antibodies: A rare association in inflammatory demyelinating diseases (2018) (20)
- Immunology of COVID‐19 and disease‐modifying therapies: The good, the bad and the unknown (2020) (20)
- De novo aphasic status epilepticus as presenting symptom of multiple sclerosis (2002) (19)
- Neuropathological Variability within a Spectrum of NMDAR‐Encephalitis (2021) (19)
- Immunopathogenic and clinical relevance of antibodies against myelin oligodendrocyte glycoprotein (MOG) in Multiple Sclerosis. (2000) (19)
- Epitope specificity of neutralizing antibodies against IFN-beta. (2004) (19)
- Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy (2021) (19)
- Validation of inter-eye difference thresholds in optical coherence tomography for identification of optic neuritis in multiple sclerosis. (2020) (18)
- Comparative study of four different assays for the detection of binding antibodies against interferon-β (2008) (18)
- Cerebral large vessel vasculitis in systemic lupus erythematosus (2014) (18)
- Seven day pre-analytical stability of serum and plasma neurofilament light chain (2021) (18)
- Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study (2009) (18)
- Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis (2020) (17)
- The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this? (2016) (17)
- Vaccination and multiple sclerosis in the era of the COVID-19 pandemic (2021) (17)
- Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity (2021) (17)
- Autoimmunity and inflammation in the peripheral nervous system (2002) (16)
- Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study (2017) (16)
- Rhythmic cued motor imagery and walking in people with multiple sclerosis: a randomised controlled feasibility study (2015) (16)
- Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination (2016) (16)
- A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta (2003) (16)
- B cells and antibodies in MS. (2010) (15)
- Management of multiple sclerosis patients in central European countries: current needs and potential solutions (2018) (15)
- Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab. (2020) (15)
- Intrathecal anti-αB-crystallin IgG antibody responses: Potential inflammatory markers in Guillain-Barré syndrome (2008) (15)
- Treatment of MOG-IgG-associated demyelination with Rituximab: a multinational study of 98 patients (2018) (15)
- Blepharochalasis. (1988) (15)
- Transient impairment of olfactory threshold in acute multiple sclerosis relapse. (2018) (15)
- Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study (2021) (15)
- B Cell Depletion and SARS‐CoV‐2 Vaccine Responses in Neuroimmunologic Patients (2022) (15)
- Multiple sclerosis - established and novel therapeutic approaches. (2010) (15)
- Distinct serum and cerebrospinal fluid cytokine and chemokine profiles in autoantibody-associated demyelinating diseases (2019) (14)
- Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders (2016) (14)
- Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis (2020) (14)
- Fibrinogen is not elevated in the cerebrospinal fluid of patients with multiple sclerosis (2011) (14)
- Diagnosis and classification of optic neuritis (2022) (14)
- Worldwide Incidence and Prevalence of Neuromyelitis Optica A Systematic Review (14)
- Genetic variants in the tumor necrosis factor receptor II gene in patients with multiple sclerosis. (2004) (13)
- Smelling multiple sclerosis: Different qualities of olfactory function reflect either inflammatory activity or neurodegeneration (2018) (13)
- New clinical implications of anti-myelin oligodendrocyte glycoprotein antibodies in children with CNS demyelinating diseases. (2018) (13)
- Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases (2021) (13)
- New insights into the burden and costs of multiple sclerosis in Europe: Results for Austria (2017) (13)
- Recommendations for the Use of Prolonged‐Release Fampridine in Patients with Multiple Sclerosis (MS) (2013) (13)
- Impairment of odor discrimination and identification is associated with disability progression and gray matter atrophy of the olfactory system in MS (2019) (13)
- Exploring cued and non-cued motor imagery interventions in people with multiple sclerosis: a randomised feasibility trial and reliability study (2018) (13)
- Evaluation of Retinal Layer Thickness Parameters as Biomarkers in a Real-World Multiple Sclerosis Cohort (2021) (13)
- Age-Dependent Seroprevalence of JCV Antibody in Children (2015) (12)
- Antibodies to aquaporin-1 are not present in neuromyelitis optica (2015) (12)
- Immunological processes related to cognitive impairment in MS (2016) (12)
- Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing–remitting multiple sclerosis in a real-world clinical setting: PROTEC (2019) (12)
- Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc (2017) (12)
- Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score (2020) (11)
- Interferon-beta 1b augments activation-induced T-cell death in multiple sclerosis patients. (1999) (11)
- Biomarkers in Multiple Sclerosis: Role of Antibodies (2006) (11)
- Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases (2020) (11)
- Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients (2016) (11)
- Effects and mechanisms of differently cued and non-cued motor imagery in people with multiple sclerosis: A randomised controlled trial (2018) (11)
- To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis. (2019) (11)
- Impact of human myelin on the maturation and function of human monocyte-derived dendritic cells. (2010) (11)
- Neurofilament light chain (2019) (10)
- Decision‐making for and impact of early immunomodulatory treatment: the Austrian Clinically Isolated Syndrome Study (ACISS) (2010) (10)
- SARS-CoV-2 antibodies in multiple sclerosis patients depending on the vaccine mode of action? (2021) (10)
- Bruton's tyrosine kinase inhibition in the treatment of preclinical models and multiple sclerosis. (2021) (10)
- Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria (2019) (9)
- Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric Study (2021) (9)
- Iron Rims in Patients With Multiple Sclerosis as Neurodegenerative Marker? A 7-Tesla Magnetic Resonance Study (2021) (9)
- Real‐life use of oral disease‐modifying treatments in Austria (2019) (9)
- Longitudinal CSF Findings in Autoimmune Encephalitis—A Monocentric Cohort Study (2021) (9)
- Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis (2012) (9)
- Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach (2020) (9)
- Cutaneous melanoma metastasizing to the iris and choroid: a case report (2002) (9)
- Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review (2021) (9)
- TNFα inhibitors as targets for protective therapies in MSA: a viewpoint (2019) (8)
- Combined evaluation of personality, risk and coping in MS patients: A step towards individualized treatment choice – The PeRiCoMS-Study I (2017) (8)
- Rethinking the importance of paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis: They do matter. (2016) (8)
- Diagnostic biomarkers in multiple sclerosis. (2007) (8)
- Progressive multifocal leukoencephalopathy complicating untreated chronic lymphatic leukemia: case report and review of the literature. (2014) (8)
- Extensive Brain Pathologic Alterations Detected with 7.0-T MR Spectroscopic Imaging Associated with Disability in Multiple Sclerosis. (2022) (8)
- No evidence for a role of rare CYP27B1 variants in Austrian multiple sclerosis patients (2014) (8)
- Is there a rationale for therapeutic immunoadsorption in multiple sclerosis? (2005) (7)
- Conversion and reversion of anti‐John Cunningham virus antibody serostatus: A prospective study (2019) (7)
- Ocular Motor Abnormalities in Anti-IgLON5 Disease (2021) (7)
- Exome-Sequence Analyses of Four Multi-Incident Multiple Sclerosis Families (2020) (7)
- Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis (2021) (7)
- Comparing humoral immune response to SARS‐CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study (2022) (7)
- Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial (2015) (7)
- Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management (2022) (7)
- Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis (2020) (7)
- Longitudinal measurement of cerebrospinal fluid neurofilament light in anti‐N‐methyl‐D‐aspartate receptor encephalitis (2020) (7)
- Predisposing Factors for Sexual Dysfunction in Multiple Sclerosis (2021) (7)
- [Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]. (2021) (6)
- Advances in Multiple Sclerosis Therapy: New Oral Disease-Modifying Agents (2010) (6)
- Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry (2021) (6)
- Progressive Multifocal Leukoencephalopathy in the Absence of Typical Radiological Changes: Can We Make a Diagnosis? (2019) (6)
- Impact of vaccination on COVID‐19 outcome in multiple sclerosis (2022) (6)
- Impact of vaccination on COVID‐19 outcome in multiple sclerosis (2022) (6)
- Second language learning induces grey matter volume increase in people with multiple sclerosis (2019) (6)
- Anti‐αB‐crystallin immunoreactivity in Guillain‐Barré syndrome and chronic inflammatory demyelinating polyneuropathy (2010) (6)
- Restless Legs Syndrome in Multiple Sclerosis: Risk factors and effect on sleep quality - a case-control study. (2021) (6)
- [Health care costs of multiple sclerosis in Austria. Cross-sectional study including consideration of quality of life]. (2004) (6)
- T cells step up after SARS-CoV-2 vaccination with B cell depletion (2021) (5)
- [Real-world evidence : Benefits and limitations in multiple sclerosis research]. (2017) (5)
- Serum neurofilament light levels correlate with change of olfactory function in multiple sclerosis (2019) (5)
- Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study (2021) (5)
- Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab—A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry (2020) (5)
- Biomarkers in the evolution of multiple sclerosis. (2017) (5)
- Guidelines should be guidelines: Time to leave the terms “consensus” and “position” for other purposes (2021) (5)
- Autoimmune Global Amnesia as Manifestation of AMPAR Encephalitis and Neuropathologic Findings (2021) (4)
- Clinical autonomic nervous system laboratories in Europe (2022) (4)
- Use of mucosal immunization with porcine zona pellucida (PZP) in mice and rabbits. (2006) (4)
- Role of MOG Antibodies in the Differential Diagnosis of Acquired Demyelinating CNS Syndromes in Children (2016) (4)
- Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations (2022) (4)
- Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis—The PaSiMS II study (2017) (4)
- Sexuality and Multiple Sclerosis: Patient and Doctor Perspectives. (2021) (4)
- Fine mapping of T-cell immunoglobulin mucin domain gene 1 failed to detect a significant association with multiple sclerosis. (2010) (4)
- Iron accumulation in the choroid plexus, ependymal cells and CNS parenchyma in a rat strain with low‐grade haemolysis of fragile macrocytic red blood cells (2020) (4)
- Selective amygdalo-hippocampectomy as a potential trigger for disease progression in multiple sclerosis (2011) (4)
- Inner nuclear layer and olfactory threshold are interlinked and reflect inflammatory activity in multiple sclerosis (2020) (4)
- Emergence of antibodies as biomarkers in multiple sclerosis (2006) (4)
- Month-of-birth-effect in multiple sclerosis in Austria (2018) (4)
- Improvement of medical judgments by numerical training in patients with multiple sclerosis (2018) (3)
- Retinal layer thinning as a biomarker of long-term disability progression in multiple sclerosis (2022) (3)
- TIRC7 and HLA-DR axis contributes to inflammation in multiple sclerosis (2014) (3)
- Oral therapies for treatment of relapsing–remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method (2020) (3)
- Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics (2014) (3)
- Polyarteritis nodosa complicating multiple myeloma - a case report and review of the literature. (2014) (3)
- Influence of physical activity on serum vitamin D levels in people with multiple sclerosis (2020) (3)
- Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry (2019) (3)
- Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter study (2022) (3)
- The Smartphone App haMSter for Tracking Patient-Reported Outcomes in People With Multiple Sclerosis: Protocol for a Pilot Study (2020) (3)
- Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions (2021) (3)
- Pathogenic autoantibodies in multiple sclerosis — from a simple idea to a complex concept (2022) (3)
- Serum hepcidin levels in multiple sclerosis (2019) (3)
- Efficacy of Teriflunomide in Early-Stage MS: Reanalysis of the TOPIC Study Using 2010 McDonald Diagnostic Criteria (P7.274) (2015) (2)
- Smoking is not associated with higher prevalence of JC virus in MS patients (2018) (2)
- Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease (2020) (2)
- European Academy of Neurology guidance for developing and reporting clinical practice guidelines on rare neurological diseases (2022) (2)
- Sternal osteomyelitis complicating percutaneous coronary artery stenting (2004) (2)
- Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis (2018) (2)
- Longitudinal measurement of CSF neurofilament light in anti-NMDAR encephalitis. (2020) (2)
- More Efficient Complement Activation by Anti–Aquaporin-4 Compared With Anti–Myelin Oligodendrocyte Glycoprotein Antibodies (2022) (2)
- Association of Cerebrospinal Fluid Parameters and Neurofilament Light Chain With Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis (2022) (2)
- Combining MRI activity with markers of myelin damage in clinically isolated syndrome suggestive of multiple sclerosis (2006) (2)
- Long‐term outcome after COVID‐19 infection in multiple sclerosis: A nation‐wide multicenter matched‐control study (2022) (2)
- Olfactory threshold predicts treatment response in relapsing multiple sclerosis (2022) (2)
- Peripheral Hemolysis in Relation to Iron Rim Presence and Brain Volume in Multiple Sclerosis (2022) (2)
- Measuring Treatment Response in Progressive Multiple Sclerosis—Considerations for Adapting to an Era of Multiple Treatment Options (2021) (2)
- Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in (2022) (2)
- Natalizumab treatment during pregnancy in multiple sclerosis—clinical and bioethical aspects of an ongoing debate (2022) (2)
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Varicella Zoster Virus Infection - Frequency of an Association (2021) (2)
- Individual Perception of Telehealth: Validation of a German Translation of the Telemedicine Perception Questionnaire and a Derived Short Version (2022) (2)
- Real-world-Evidenz (2017) (1)
- Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination (2017) (1)
- [The corona pandemic and multiple sclerosis: vaccinations and their implications for patients-Part 2: vaccine technologies]. (2021) (1)
- Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder (2022) (1)
- Incidence and clinical spectrum of rhabdomyolysis in general neurology: a retrospective cohort study (2021) (1)
- A 45‐YEAR OLD MALE WITH LEFT‐SIDED HEMIHYPESTHESIA (2010) (1)
- Immunosenescence and multiple sclerosis. (2022) (1)
- Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years (2021) (1)
- Karl Vass, 1958–2012 (2012) (1)
- Progressive multifocal leukoencephalopathy (2018) (1)
- Feasibility of a smartphone app to monitor patient reported outcomes in multiple sclerosis: The haMSter interventional trial (2022) (1)
- Bioavailability of beta interferon 1b in MS patients with and without neutralising antibodies (1998) (1)
- Estimating Risk of Multiple Sclerosis Disease Reactivation in Pregnancy and Postpartum: The VIPRiMS Score (2022) (1)
- Alemtuzumab induced hemodynamic change in relapsing multiple sclerosis occurs independent of corticosteroid premedication - a retrospective multicentre study. (2022) (1)
- Has the pandemic changed treatment strategy in multiple sclerosis? (2022) (1)
- Multiple Sclerosis (2004) (1)
- [The corona pandemic and multiple sclerosis: vaccinations and their implications for patients-Part 1: recommendations]. (2021) (1)
- Functional Recovery in Autoimmune Encephalitis: A Prospective Observational Study (2021) (1)
- Autoantibodies as paraclinical markers in multiple sclerosis (2005) (1)
- Correction to: Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry (2019) (1)
- [Myalgic encephalomyelitis/chronic fatigue syndrome: an overview of current evidence]. (2023) (1)
- Multiple sclerosis (PP-038) (2010) (1)
- Distinct Patterns of Humoral and Cellular Immune Responses Following SARS-CoV-2 mRNA Vaccination in Patients With Immune-Mediated Neurological Disorders on Anti-CD20 Therapy: A Prospective Cohort Study (2021) (1)
- Lesion-Specific Metabolic Alterations in Relapsing-Remitting Multiple Sclerosis Via 7 T Magnetic Resonance Spectroscopic Imaging (2022) (1)
- Biological Markers of Prognostic Value in Multiple Sclerosis (2008) (1)
- Early intervention in multiple sclerosis: how can we maximise patient prospects? (2017) (1)
- Bright light therapy as a non-pharmacological treatment option for multiple sclerosis-related fatigue: A randomized sham-controlled trial (2022) (1)
- University of Southern Denmark Worldwide Incidence and Prevalence of Neuromyelitis Optica (0)
- Commentary on “Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis” (2020) (0)
- Axonal Loss Independent of Demyelination in Multiple Sclerosis (2006) (0)
- ADEM-Like Presentation as the Main Manifestation of X-Linked Lymphoproliferative Disease in a 4-Year-Old Male Patient (2015) (0)
- EAE in Lewis rats: comparison of pathogenetic T-cell responses to MBP, MOG, MAG, GFAP and S-100β protein (1994) (0)
- Stability of Anti-JCV Antibody Index in Multiple Sclerosis: A 6-Year Longitudinal Study (P3.067) (2016) (0)
- Temporal and spatial patterns of inflammation and oxidative injury in human SCI (653) (2020) (0)
- DFP/CME: Therapie-Update Multiple Sklerose // Update – Therapy of multiple sclerosis (2020) (0)
- [Clinical aspects and diagnosis of multiple sclerosis]. (1996) (0)
- Commentary to "Letter to the editor: To treat or not to treat study - Comparative group inclusion considerations" for multiple sclerosis and related disorders. (2020) (0)
- serum and cerebrospinal fluid Aqp4-igg in patients with neuromyelitis optica spectrum disorders: a follow-up study in six patients : p1705 (2010) (0)
- Antibody to aquaporin-4: serum levels correlate with clinical disease activity (2008) (0)
- Myelin associated glycoprotein: A target autoantigen in experimental autoimmune encephalitis (1994) (0)
- Anti-MOG Antibodies as Early Predictors for Conversion to Relapsing-Remitting Disease Course in Patients Suggestive of Multiple Sclerosis (2004) (0)
- Reader response: Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study (2020) (0)
- Decision making and framing effects in multiple sclerosis (2020) (0)
- DFP/CME: Update: Primäre progrediente Multiple Sklerose (PPMS) // Primary progressive multiple sclerosis (PPMS) – an update (2018) (0)
- Are cytokines and adhesion molecules useful parameters to differentiate bacterial from fungal ventriculitis? (2001) (0)
- Diagnostic approach and treatment regimens in adult patients suffering from antibody-mediated or paraneoplastic encephalitis. (2022) (0)
- A Case of Eight-and-a-Half-Syndrome as a Presenting Manifestation ofLate Onset Multiple Sclerosis (2016) (0)
- Anti-MOG antibody responses in multiple sclerosis(1): Reliable testsystems provide reliable results (1998) (0)
- Escalation therapy for multiple sclerosis in Austria: analysis of gender differences in the nationwide registry (P2.404) (2017) (0)
- TCRM_A_257714 651..662 (2020) (0)
- Apolipoprotein E &egr;4 is associated with rapid progression of multiple sclerosis (2001) (0)
- International multicenter examination of MOG antibody assays (vol 7, e674, 2020) (2020) (0)
- Olfactory threshold predicts short term relapse activity in relapsing-remitting multiple sclerosis (P2.347) (2017) (0)
- A Highly Sensitive Live Cell Based Assay for Detection of Antibodies Against N-methyl-d-aspartate Receptors (2014) (0)
- Odor identification is associated with neurodegeneration in relapsing-remitting multiple sclerosis (P2.360) (2017) (0)
- TNFα inhibitors as targets for protective therapies in MSA: a viewpoint (2019) (0)
- Application of diagnostic criteria for optic neuritis – Authors' reply (2023) (0)
- Clinical and Radiological Features of Children with MOG-positive and MOG-negative ADEM (2014) (0)
- Disease Course in Elderly MS Patients (P2.084) (2016) (0)
- Treatment of Multiple Sclerosis with Natalizumab: Experiences from a Real-Life Cohort Over 15 Years (2021) (0)
- T-cells against MBP, MOG, MAG, GFAP and S100β induce antigen specific pathological features of nervous system inflammation in EAE (1995) (0)
- Replication study of multiple sclerosis (MS) susceptibility alleles and correlation of DNA-variants with disease features in a cohort of Austrian MS patients (2012) (0)
- Multiple sclerosis. (2004) (0)
- Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab (2022) (0)
- Anti-MOG antibody response in multiple sclerosis: A first step towards an immunopathological subtype of MS? (1998) (0)
- Relationship between Heat Intolerance and Response to Prolonged-Release Fampridine in Patients with Multiple Sclerosis (P07.078) (2012) (0)
- Smoking is not associated with higher prevalence of JC virus in MS patients (2018) (0)
- FLAIR2 post-processing: improving MS lesion detection in standard MS imaging protocols (2021) (0)
- Addition of optic nerve involvement to dissemination in space criteria for multiple sclerosis – the value of optical coherence tomography (S46.009) (2023) (0)
- Multifactorial White Matter Damage in the Acute Phase and Pre-Existing Conditions May Drive Cognitive Dysfunction after SARS-CoV-2 Infection: Neuropathology-Based Evidence (2023) (0)
- Tumefactive multiple sclerosis presents with painless progressive hemiparesis and aphasia (2023) (0)
- Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study (2023) (0)
- Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR). (2023) (0)
- Retinal Layer Thinning After Optic Neuritis Is Associated With Future Relapse Remission in Relapsing Multiple Sclerosis (2022) (0)
- Real-world operation of multiple sclerosis centres in Central-Eastern European countries covering 107 million inhabitants. (2022) (0)
- Retinal layer thickness predicts disability accumulation in early relapsing multiple sclerosis (2023) (0)
- Immunosenescence in Neurological Diseases—Is There Enough Evidence? (2022) (0)
- Author Correction: Seven day pre-analytical stability of serum and plasma neurofilament light chain (2022) (0)
- Correction to: FLAIR2 post-processing: improving MS lesion detection in standard MS imaging protocols (2021) (0)
- Correction to: Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk (2021) (0)
- Metabolic Insights into Iron Deposition in Relapsing-Remitting Multiple Sclerosis via 7T Magnetic Resonance Spectroscopic Imaging (2023) (0)
- Imaging features to distinguish AQP4-positive NMOSD and MS at disease onset: A retrospective analysis in a single-center cohort. (2021) (0)
- Association of paramagnetic rim lesions and retinal layer thickness in patients with multiple sclerosis (2022) (0)
- Remote visits for people with multiple sclerosis during the COVID-19 pandemic in Austria: The TELE MS randomized controlled trial (2022) (0)
- Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis (2021) (0)
- Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk (2021) (0)
- Screening for osteoporosis in people with MS: A new risk score. (2023) (0)
- Neuroradiological differentiation of white matter lesions in patients with multiple sclerosis and Fabry disease (2022) (0)
- High Anti-CoV2S Antibody Levels at Hospitalization Are Associated with Improved Survival in Patients with COVID-19 Vaccine Breakthrough Infection (2022) (0)
- Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study (S46.004) (2023) (0)
- Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome (2020) (0)
- Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis (2023) (0)
- Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria. (2023) (0)
- What adverse events occur with disease-modifying therapy in multiple sclerosis? (2012) (0)
- Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders (2016) (0)
- Longitudinal stability of anti–JC virus (JCV) antibody index over 2 years in multiple sclerosis (MS) patients treated with natalizumab in the ASCEND study (P4.2-009) (2019) (0)
- Kurt Jellinger 90: his contribution to neuroimmunology (2021) (0)
- A case of primary optic pathway demyelination caused by oncocytic oligodendrogliopathy of unknown origin (2022) (0)
- Nervous System Diseases Central Patients with Different Inflammatory Oligodendrocyte Glycoprotein Recognized by Conformational Epitopes on Myelin Distinction and Temporal Stability of (2013) (0)
- Impact of Brexit on Chemical Compliance in Europe (2021) (0)
- Prioritization process for EAN clinical practice guidelines. (2022) (0)
- Reply to letter to the editor: Olfactory threshold as a biomarker of disease activity. (2022) (0)
- Prioritization process for European Academy of Neurology clinical practice guidelines (2023) (0)
- P11.18.A Localizing value of EEG recordings in patients with glioblastoma (2022) (0)
- Usability Testing: Raising the Bar for Scientific Data Portals (2019) (0)
- Impact of the COVID‐19 pandemic on clinical autonomic practice in Europe: a survey of the European Academy of Neurology and the European Federation of Autonomic Societies (2023) (0)
- EAN guidance for developing and reporting clinical practice guidelines on rare neurological diseases (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Thomas Berger?
Thomas Berger is affiliated with the following schools:
